Molecular and clinical endocrinology of the endometrium;Molekulare und klinische endokrinologie des endometriums

Pathologe

Volumn 20, Issue 1, 1999, Pages 50-55

  Bamberger, Ana Maria ^a   Kleinkauf Houcken, Annette ^a   Bamberger, Ch M ^a   Loning Th ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Abteilung fur Gynakopathologie   (Germany)

Author keywords

Endometrium; Hormone replacement therapy; Molecular endocrinology; Tamoxifen; Vaginal sonography

Indexed keywords

ANTIESTROGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; GROWTH FACTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FEMALE; GENETIC TRANSCRIPTION; HORMONAL CARCINOGENESIS; HORMONE SUBSTITUTION; HUMAN; THICKNESS; TRANSVAGINAL ECHOGRAPHY;

BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTORS, ESTRADIOL; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY;

EID: 0032979221     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002920050319     Document Type: Article

References (37)

1. Achiron R, Lipitz S, Sivan E, Goldenberg M, Mashiach S (1995) Sonohysterography for ultrasonographic evaluation of tamoxifen- associated cystic thickened endometrium. J Ultrasound Med 14:685-688
2. Bakos O, Lundkvist O, Bergh T (1993) Transvaginal sonographic evaluation of endometrial growth and texture in spontaneous ovulatory cycles - a descriptive study. Hum Reprod 8:799-806
3. Bamberger AM, Bamberger CM, Gellersen B, Schulte HM (1996) Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci USA 93:6169-6174
4. Bamberger AM, Erdmann I, Bamberger CM, Jenatschke SS, Schulte HM (1997a) Transcriptional regulation of the human 'leukemia inhibitory factor' gene: modulation by glucocorticoids and estradiol. Mol Cell Endocrinol 127:71-79
5. Bamberger AM, Erdmann I, Jenatschke S, Bamberger CM, Schulte HM (1997b) Regulation of the human leukaemia inhibitory factor (LIF) promoter in HEC-1B endometrial adenocarcinoma cells. Mol Hum Reprod 3:789-793
6. Benedetto MT, Tabanelli S, Gurpide E (1990) Estrone sulfate sulfatase activity is increased during in vitro decidualization of stromal cells from human endometrium. J Clin Endocrinol Metab 70:342-345
7. Casper RF (1996) Regulation of estrogen/ progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 41:16-21
8. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, LiVolsi VA (1992) Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79:111-116
9. Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman P, Bullerdiek J, Van den Berghe H (1998) Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 58:2278-2281
10. Dallenbach-Hellweg G, Hahn U (1995) Mutinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 14:7-15
11. Dallenbach-Hellweg G, Poulsen H (1996) Atlas of endometrial histopathology. Springer, Berlin Heidelberg New York
12. Dallenbach-Hellweg G (1997) Histopathology of functional and neoplastic changes in cervix and endometrium. Verh Dtsch Ges Pathol 81:240-244
13. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127-130
14. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women (see comments). N Engl J Med 337:1641-1647
15. Giudice LC, Saleh W (1995) Growth factors in reproduction. TEM 6:60-69
16. Goldstein SR (1994) Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen (see comments). Am J Obstet Gynecol 170:447-451
17. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG (1991) Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 164:47-52
18. Granberg S, Ylostalo P, Wikland M, Karlsson B (1997) Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas 27:35-40
19. Grenman SE, Roberts JA, England BG, Gronroos M, Carey TE (1988) In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate. Gynecol Oncol 30:239-250
20. Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR (1997) Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Roentgenol 168:657-661
21. Heller DS (1994) The endometrium: a clinicopathologic approach. Igaku-Shoin, New York
22. Ismail SM (1994) Pathology of endometrium treated with tamoxifen (see comments). J Clin Pathol 47:827-833
23. Ismail SM (1996) The effects of tamoxifen on the uterus. Curr Opin Obstet Gynecol 8:27-31
24. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial (see comments). N Engl J Med 337:1792-1798
25. Leidenberger FA (1998) Klinische Endokrinologie für Frauenärzte. Springer, Berlin Heidelberg New York
26. Loffer FD (1989) Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 73:16-20
27. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF (1998) Abnormalities detected on transvaginal ultrasonography in tamoxifen- treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178:1145-1150
28. Nagele F, O'Connor H, Davies A, Badawy A, Mohamed H, Magos A (1996) 2500 Outpatient diagnostic hysteroscopies (see comments). Obstet Gynecol 88:87-92
29. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459
30. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B (1989) Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 8:125-131
31. O'Malley B (1990) The steroid receptorsuperfamily: more excitement predicted for the future. Mol Endocrinol 4:363-369
32. O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT, Tsai MJ (1991) Molecular mechanism of action of a steroid hormone receptor. Recent Prog Norm Res 47:1-24
33. Opinion (1996) Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 53:197-196
34. Ortmann O (1997) Die Bedeutung von Tamoxifen als Substitutionstherapie in der Postmenopause. In: Braendle W, Schulz KD (Hrsg)Hormone und Mammakarzinom. Zuckschwerdt, München, S 118-125
35. Pfahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14:651-658
36. Rodriguez GC, Yaqub N, King ME (1993) A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol 168:55-59
37. Samsioe G (1996) Hormone replacement therapy: aspects of bleeding problems and compliance, Int J Fertil Menopausal Stud 41:11-15